Search Dental Tribune

3D-printable materials powered by Remora technology gain regulatory clearance in North America and Canada

Remora’s technology disrupts bacterial communication through quorum sensing, a mechanism modelled after the natural defences of the red algae Delisea pulchra. (Image: National Museum of Nature and Science, Tokyo/CC0 1.0, changes made)

Thu. 16 January 2025

save

GLASGOW, Scotland: New biocompatible materials for 3D printing and milling that employ the unique Remora anti-biofilm technology have gained clearance from both the US Food and Drug Administration and Health Canada. These new materials—the printodent GR-10 guide | MSI and printodent GR-19.1 OA | MSI resins and the THERMEO milling blanks—are for the fabrication of dental devices such as splints and are now available for use in dental settings across the US and Canada.

The trademark of Scotland-based clean technology startup Penrhos Bio, the patented Remora technology disrupts the communication of bacteria by mimicking the natural protective mechanism of the red seaweed Delisea pulchra, significantly reducing biofilm build-up on surfaces. This innovative technology is the result of a pioneering collaboration with pro3dure medical, a leader in 3D-printing materials for medical applications, and with Unilever. In recognition of the achievements of their collaboration, the three companies were given the Innovative Collaboration Award at the annual Scotland’s Life Sciences Awards in Glasgow last year.

Dr Yvonne Davies, chief commercial officer at Remora, emphasised how the clearance underscores both the safety and the functionality of Remora technologies. (Image: Remora)

Commenting on the clearance, Dr Yvonne Davies, chief commercial officer at Remora, said: “We are thrilled to be working with pro3dure medical to combine our innovative approaches in order to enhance the use of Remora technology in our material portfolio. Having regulatory clearance in the United States and Canada is a testament to the efficacy and safety of our products, and it marks a significant step forward for Remora.”

“Gaining FDA and Health Canada approval not only validates our technology but also opens up new opportunities for us to expand our impact in the dental industry. We are committed to continuing our mission to prevent harmful biofilms and improve health outcomes globally,” she continued.

Dr Gary Jernberg, the US dental specialist who was involved in the development of the products, said: “Achieving FDA and Health Canada approval for 3D-printable dental devices is a monumental achievement for Remora. This approval not only underscores the safety and efficacy of the Remora technology but also positions the company as a leader in the prevention of harmful biofilms within the dental industry.”

He added: “The ability to significantly reduce biofilm and plaque build-up on dental devices is a game-changer for both dental professionals and patients. I am excited about the potential to expand further into the global dental sector and support Remora as it continues its mission to improve health outcomes worldwide.”

Tags:
To post a reply please login or register
advertisement
advertisement